TR 354 Mouse Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus DIMETHOXANE DATE: 09/05/94
EXPERIMENT: 05038 TEST: 02 TIME: 09:14:02
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: N01CP9565302 ROUTE: GAVAGE NTP C#: 56213
PATHOLOGIST: J. TOFT S. EUSTIS CAS: 828-00-2
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus DIMETHOXANE DATE: 09/05/94
EXPERIMENT: 05038 TEST: 02 TIME: 09:14:02
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01CP9565302 ROUTE: GAVAGE NTP C#: 56213
PATHOLOGIST: J. TOFT S. EUSTIS CAS: 828-00-2
MICE(B6C3F1)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Gland
Bone Marrow
Brain
Epididymis
Gallbladder
Heart
Islets, Pancreatic
Kidney
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Columbus DIMETHOXANE DATE: 09/05/94
EXPERIMENT: 05038 TEST: 02 TIME: 09:14:02
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01CP9565302 ROUTE: GAVAGE NTP C#: 56213
PATHOLOGIST: J. TOFT S. EUSTIS CAS: 828-00-2
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF DIMETHOXANE
====================================================================================================
MALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Liver Hepatocellular Carcinoma or Hepatocellular Adenoma
Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma
Lung Alveolar/Bronchiolar Carcinoma
Stomach, Forestomach Squamous Cell Carcinoma or Papilloma Squamous
Squamous Cell Papilloma
All Organs Malignant Lymphoma And Histiocytic Sarcoma
Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed,
NOS, or Undifferentiated Cell Type
Benign Tumors
Malignant Tumors
====================================================================================================
FEMALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
All Organs Benign Tumors
====================================================================================================
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 6/50 (12%) 0/21 (0%) 3/50 (6%) | 0/50 (0%) 0/14 (0%) 1/50 (2%) |
|ADJUSTED (b) | 18.2% 0.0% 10.3% | 0.0% 0.0% 2.9% |
|TERMINAL (d) | 6/33 (18%) 0/0 3/29 (10%) | 0/36 (0%) 0/0 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 731 (T) --- 731 (T) | --- --- 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.246N (e) P=0.306N | P=0.298 (e) P=0.489 |
|INCIDENTAL TUMOR | P=0.246N (e) P=0.306N | P=0.298 (e) P=0.489 |
|LOGISTIC REGRESSION | P=0.246N (e) P=0.306N | P=0.298 (e) P=0.489 |
|COCHRAN-ARMITAGE | P=0.170N | P=0.296 |
|FISHER EXACT | P=0.111N P=0.243N | (e) P=0.500 |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/21 (0%) 0/50 (0%) | 1/49 (2%) 0/14 (0%) 1/50 (2%) |
|ADJUSTED (b) | 6.1% 0.0% 0.0% | 2.9% 0.0% 2.9% |
|TERMINAL (d) | 2/33 (6%) 0/0 0/29 (0%) | 1/35 (3%) 0/0 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 731 (T) --- --- | 731 (T) --- 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.164N (e) P=0.267N | P=0.631 (e) P=0.755 |
|INCIDENTAL TUMOR | P=0.164N (e) P=0.267N | P=0.631 (e) P=0.755 |
|LOGISTIC REGRESSION | P=0.164N (e) P=0.267N | P=0.631 (e) P=0.755 |
|COCHRAN-ARMITAGE | P=0.120N | P=0.643N |
|FISHER EXACT | P=0.493N P=0.247N | P=0.778N P=0.747N |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Harderian Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/48 (4%) 2/50 (4%) | 2/50 (4%) 0/49 (0%) 1/50 (2%) |
|ADJUSTED (b) | 6.1% 7.4% 6.0% | 5.6% 0.0% 2.6% |
|TERMINAL (d) | 2/33 (6%) 2/27 (7%) 1/29 (3%) | 2/36 (6%) 0/35 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 731 (T) 731 (T) 668 | 731 (T) --- 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.555 P=0.622 P=0.659 | P=0.374N P=0.244N P=0.516N |
|INCIDENTAL TUMOR | P=0.571 P=0.622 P=0.679 | P=0.277N P=0.244N P=0.394N |
|LOGISTIC REGRESSION | P=0.561 P=0.622 P=0.670 | P=0.367N P=0.244N P=0.508N |
|COCHRAN-ARMITAGE | P=0.600 | P=0.361N |
|FISHER EXACT | P=0.676 P=0.691N | P=0.253N P=0.500N |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/48 (4%) 2/50 (4%) | 2/50 (4%) 0/49 (0%) 2/50 (4%) |
|ADJUSTED (b) | 6.1% 7.4% 6.0% | 5.6% 0.0% 5.5% |
|TERMINAL (d) | 2/33 (6%) 2/27 (7%) 1/29 (3%) | 2/36 (6%) 0/35 (0%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 731 (T) 731 (T) 668 | 731 (T) --- 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.555 P=0.622 P=0.659 | P=0.606 P=0.244N P=0.676 |
|INCIDENTAL TUMOR | P=0.571 P=0.622 P=0.679 | P=0.551N P=0.244N P=0.620N |
|LOGISTIC REGRESSION | P=0.561 P=0.622 P=0.670 | P=0.614 P=0.244N P=0.686 |
|COCHRAN-ARMITAGE | P=0.600 | P=0.621 |
|FISHER EXACT | P=0.676 P=0.691N | P=0.253N P=0.691N |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Liver |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/49 (6%) 1/28 (4%) 2/50 (4%) | 1/50 (2%) 0/19 (0%) 0/50 (0%) |
|ADJUSTED (b) | 7.8% 14.3% 6.5% | 2.8% 0.0% 0.0% |
|TERMINAL (d) | 1/33 (3%) 1/7 (14%) 1/29 (3%) | 1/36 (3%) 0/5 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 664 731 (T) 697 | 731 (T) --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.455N P=0.617N P=0.543N | P=0.312N P=0.876N P=0.511N |
|INCIDENTAL TUMOR | P=0.395N P=0.634N P=0.462N | P=0.312N P=0.876N P=0.511N |
|LOGISTIC REGRESSION | P=0.436N P=0.691N P=0.513N | P=0.312N P=0.876N P=0.511N |
|COCHRAN-ARMITAGE | P=0.398N | P=0.292N |
|FISHER EXACT | P=0.538N P=0.490N | P=0.725N P=0.500N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 7/49 (14%) 5/28 (18%) 13/50 (26%) | 7/50 (14%) 3/19 (16%) 4/50 (8%) |
|ADJUSTED (b) | 19.9% 34.3% 37.8% | 19.4% 41.5% 11.2% |
|TERMINAL (d) | 6/33 (18%) 2/7 (29%) 9/29 (31%) | 7/36 (19%) 2/5 (40%) 3/34 (9%) |
|FIRST INCIDENCE (DAYS) | 530 446 550 | 731 (T) 680 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.056 P=0.183 P=0.069 | P=0.256N P=0.186 P=0.292N |
|INCIDENTAL TUMOR | P=0.068 P=0.241 P=0.087 | P=0.188N P=0.219 P=0.236N |
|LOGISTIC REGRESSION | P=0.075 P=0.327 P=0.094 | P=0.243N P=0.215 P=0.282N |
|COCHRAN-ARMITAGE | P=0.090 | P=0.219N |
|FISHER EXACT | P=0.456 P=0.115 | P=0.560 P=0.262N |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 9/49 (18%) 10/28 (36%) 6/50 (12%) | 2/50 (4%) 2/19 (11%) 1/50 (2%) |
|ADJUSTED (b) | 21.7% 63.8% 16.9% | 4.8% 21.8% 2.9% |
|TERMINAL (d) | 4/33 (12%) 4/7 (57%) 3/29 (10%) | 1/36 (3%) 1/5 (20%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 509 448 423 | 462 617 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.353N P=0.053 P=0.359N | P=0.416N P=0.381 P=0.516N |
|INCIDENTAL TUMOR | P=0.284N P=0.089 P=0.290N | P=0.487N P=0.251 P=0.513N |
|LOGISTIC REGRESSION | P=0.226N P=0.083 P=0.188N | P=0.381N P=0.421 P=0.466N |
|COCHRAN-ARMITAGE | P=0.248N | P=0.402N |
|FISHER EXACT | P=0.079 P=0.274N | P=0.303 P=0.500N |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 14/49 (29%) 12/28 (43%) 19/50 (38%) | 8/50 (16%) 5/19 (26%) 4/50 (8%) |
|ADJUSTED (b) | 35.2% 76.4% 51.0% | 21.1% 61.9% 11.2% |
|TERMINAL (d) | 9/33 (27%) 5/7 (71%) 12/29 (41%) | 7/36 (19%) 3/5 (60%) 3/34 (9%) |
|FIRST INCIDENCE (DAYS) | 509 446 423 | 462 617 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.116 P=0.042 * P=0.137 | P=0.190N P=0.078 P=0.205N |
|INCIDENTAL TUMOR | P=0.130 P=0.067 P=0.178 | P=0.161N P=0.057 P=0.160N |
|LOGISTIC REGRESSION | P=0.180 P=0.113 P=0.231 | P=0.170N P=0.176 P=0.186N |
|COCHRAN-ARMITAGE | P=0.192 | P=0.159N |
|FISHER EXACT | P=0.153 P=0.217 | P=0.257 P=0.178N |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 14/49 (29%) 12/28 (43%) 19/50 (38%) | 8/50 (16%) 5/19 (26%) 4/50 (8%) |
|ADJUSTED (b) | 35.2% 76.4% 51.0% | 21.1% 61.9% 11.2% |
|TERMINAL (d) | 9/33 (27%) 5/7 (71%) 12/29 (41%) | 7/36 (19%) 3/5 (60%) 3/34 (9%) |
|FIRST INCIDENCE (DAYS) | 509 446 423 | 462 617 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.116 P=0.042 * P=0.137 | P=0.190N P=0.078 P=0.205N |
|INCIDENTAL TUMOR | P=0.130 P=0.067 P=0.178 | P=0.161N P=0.057 P=0.160N |
|LOGISTIC REGRESSION | P=0.180 P=0.113 P=0.231 | P=0.170N P=0.176 P=0.186N |
|COCHRAN-ARMITAGE | P=0.192 | P=0.159N |
|FISHER EXACT | P=0.153 P=0.217 | P=0.257 P=0.178N |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 8/49 (16%) 2/25 (8%) 9/50 (18%) | 3/50 (6%) 1/14 (7%) 4/50 (8%) |
|ADJUSTED (b) | 23.0% 27.3% 28.4% | 8.3% 0.0% 11.8% |
|TERMINAL (d) | 7/33 (21%) 1/4 (25%) 7/29 (24%) | 3/36 (8%) 0/0 4/34 (12%) |
|FIRST INCIDENCE (DAYS) | 549 662 551 | 731 (T) 623 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.343 P=0.603 P=0.395 | P=0.398 P=0.505 P=0.468 |
|INCIDENTAL TUMOR | P=0.394 P=0.646 P=0.458 | P=0.344 P=0.473 P=0.468 |
|LOGISTIC REGRESSION | P=0.386 P=0.640N P=0.450 | P=0.408 P=0.580 P=0.468 |
|COCHRAN-ARMITAGE | P=0.461 | P=0.422 |
|FISHER EXACT | P=0.271N P=0.518 | P=0.638 P=0.500 |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 2/25 (8%) 4/50 (8%) | 1/50 (2%) 0/14 (0%) 1/50 (2%) |
|ADJUSTED (b) | 0.0% 50.0% 10.6% | 2.8% 0.0% 2.3% |
|TERMINAL (d) | 0/33 (0%) 2/4 (50%) 1/29 (3%) | 1/36 (3%) 0/0 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | --- 731 (T) 550 | 731 (T) --- 634 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.046 * P=0.002 ** P=0.060 | P=0.648N (e) P=0.753N |
|INCIDENTAL TUMOR | P=0.059 P=0.002 ** P=0.092 | P=0.539 (e) P=0.614 |
|LOGISTIC REGRESSION | P=0.051 P=0.002 ** P=0.076 | P=0.647 (e) P=0.761N |
|COCHRAN-ARMITAGE | P=0.053 | P=0.648N |
|FISHER EXACT | P=0.111 P=0.061 | P=0.781N P=0.753N |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 8/49 (16%) 4/25 (16%) 13/50 (26%) | 4/50 (8%) 1/14 (7%) 5/50 (10%) |
|ADJUSTED (b) | 23.0% 75.8% 36.7% | 11.1% 0.0% 13.8% |
|TERMINAL (d) | 7/33 (21%) 3/4 (75%) 8/29 (28%) | 4/36 (11%) 0/0 4/34 (12%) |
|FIRST INCIDENCE (DAYS) | 549 662 550 | 731 (T) 623 634 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.085 P=0.086 P=0.111 | P=0.409 P=0.505 P=0.477 |
|INCIDENTAL TUMOR | P=0.116 P=0.103 P=0.161 | P=0.307 P=0.473 P=0.384 |
|LOGISTIC REGRESSION | P=0.105 P=0.169 P=0.146 | P=0.416 P=0.620 P=0.483 |
|COCHRAN-ARMITAGE | P=0.141 | P=0.430 |
|FISHER EXACT | P=0.625N P=0.176 | P=0.701N P=0.500 |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/48 (0%) 0/50 (0%) | 1/50 (2%) 0/49 (0%) 2/50 (4%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 2.8% 0.0% 5.3% |
|TERMINAL (d) | 0/33 (0%) 0/27 (0%) 0/29 (0%) | 1/36 (3%) 0/35 (0%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 731 (T) --- 653 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.358 P=0.506N P=0.495 |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.447 P=0.506N P=0.606 |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.356 P=0.506N P=0.493 |
|COCHRAN-ARMITAGE | (e) | P=0.361 |
|FISHER EXACT | (e) (e) | P=0.505N P=0.500 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/48 (0%) 0/50 (0%) | 1/50 (2%) 0/49 (0%) 3/50 (6%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 2.8% 0.0% 8.1% |
|TERMINAL (d) | 0/33 (0%) 0/27 (0%) 0/29 (0%) | 1/36 (3%) 0/35 (0%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 731 (T) --- 653 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.172 P=0.506N P=0.298 |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.225 P=0.506N P=0.380 |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.171 P=0.506N P=0.297 |
|COCHRAN-ARMITAGE | (e) | P=0.177 |
|FISHER EXACT | (e) (e) | P=0.505N P=0.309 |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma, Carcinoma, or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/48 (0%) 0/50 (0%) | 1/50 (2%) 0/49 (0%) 3/50 (6%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 2.8% 0.0% 8.1% |
|TERMINAL (d) | 0/33 (0%) 0/27 (0%) 0/29 (0%) | 1/36 (3%) 0/35 (0%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 731 (T) --- 653 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.172 P=0.506N P=0.298 |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.225 P=0.506N P=0.380 |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.171 P=0.506N P=0.297 |
|COCHRAN-ARMITAGE | (e) | P=0.177 |
|FISHER EXACT | (e) (e) | P=0.505N P=0.309 |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/46 (0%) 0/20 (0%) 0/41 (0%) | 6/47 (13%) 4/19 (21%) 6/45 (13%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 16.8% 66.7% 17.0% |
|TERMINAL (d) | 0/33 (0%) 0/0 0/27 (0%) | 5/34 (15%) 4/6 (67%) 5/34 (15%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 629 731 (T) 688 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.557N P=0.064 P=0.619N |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.558 P=0.059 P=0.604 |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.539N P=0.102 P=0.612N |
|COCHRAN-ARMITAGE | (e) | P=0.525 |
|FISHER EXACT | (e) (e) | P=0.309 P=0.589 |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/46 (0%) 1/20 (5%) 0/41 (0%) | 6/47 (13%) 4/19 (21%) 6/45 (13%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 16.8% 66.7% 17.0% |
|TERMINAL (d) | 0/33 (0%) 0/0 0/27 (0%) | 5/34 (15%) 4/6 (67%) 5/34 (15%) |
|FIRST INCIDENCE (DAYS) | --- 509 --- | 629 731 (T) 688 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.714 P=0.464 (e) | P=0.557N P=0.064 P=0.619N |
|INCIDENTAL TUMOR | P=0.708 P=0.545 (e) | P=0.558 P=0.059 P=0.604 |
|LOGISTIC REGRESSION | P=0.721N P=0.507 (e) | P=0.539N P=0.102 P=0.612N |
|COCHRAN-ARMITAGE | P=0.693 | P=0.525 |
|FISHER EXACT | P=0.303 (e) | P=0.309 P=0.589 |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/48 (0%) 4/50 (8%) | 0/50 (0%) 0/49 (0%) 0/50 (0%) |
|ADJUSTED (b) | 6.1% 0.0% 13.1% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 2/33 (6%) 0/27 (0%) 3/29 (10%) | 0/36 (0%) 0/35 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 731 (T) --- 697 | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.189 P=0.283N P=0.281 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.208 P=0.283N P=0.305 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.192 P=0.282N P=0.284 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.223 | (e) |
|FISHER EXACT | P=0.258N P=0.339 | (e) (e) |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Fibrosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 10/50 (20%) 10/48 (21%) 5/50 (10%) | 1/50 (2%) 3/49 (6%) 2/50 (4%) |
|ADJUSTED (b) | 24.1% 29.2% 13.6% | 2.2% 7.2% 5.5% |
|TERMINAL (d) | 3/33 (9%) 4/27 (15%) 1/29 (3%) | 0/36 (0%) 1/35 (3%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 519 551 549 | 596 601 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.185N P=0.402 P=0.197N | P=0.398 P=0.322 P=0.488 |
|INCIDENTAL TUMOR | P=0.056N P=0.469 P=0.071N | P=0.241 P=0.260 P=0.467 |
|LOGISTIC REGRESSION | P=0.063N P=0.574 P=0.084N | P=0.424 P=0.295 P=0.512 |
|COCHRAN-ARMITAGE | P=0.115N | P=0.400 |
|FISHER EXACT | P=0.558 P=0.131N | P=0.301 P=0.500 |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Neurofibrosarcoma, Fibrosarcoma, Sarcoma, |
| Neurofibroma, or Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 12/50 (24%) 10/48 (21%) 9/50 (18%) | 1/50 (2%) 3/49 (6%) 2/50 (4%) |
|ADJUSTED (b) | 29.2% 29.2% 25.1% | 2.2% 7.2% 5.5% |
|TERMINAL (d) | 5/33 (15%) 4/27 (15%) 4/29 (14%) | 0/36 (0%) 1/35 (3%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 519 551 549 | 596 601 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.374N P=0.563 P=0.419N | P=0.398 P=0.322 P=0.488 |
|INCIDENTAL TUMOR | P=0.188N P=0.550N P=0.246N | P=0.241 P=0.260 P=0.467 |
|LOGISTIC REGRESSION | P=0.200N P=0.459N P=0.265N | P=0.424 P=0.295 P=0.512 |
|COCHRAN-ARMITAGE | P=0.269N | P=0.400 |
|FISHER EXACT | P=0.447N P=0.312N | P=0.301 P=0.500 |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Neurofibrosarcoma, Fibrosarcoma, or Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 10/50 (20%) 10/48 (21%) 6/50 (12%) | 1/50 (2%) 3/49 (6%) 2/50 (4%) |
|ADJUSTED (b) | 24.1% 29.2% 16.1% | 2.2% 7.2% 5.5% |
|TERMINAL (d) | 3/33 (9%) 4/27 (15%) 1/29 (3%) | 0/36 (0%) 1/35 (3%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 519 551 549 | 596 601 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.263N P=0.402 P=0.287N | P=0.398 P=0.322 P=0.488 |
|INCIDENTAL TUMOR | P=0.093N P=0.469 P=0.116N | P=0.241 P=0.260 P=0.467 |
|LOGISTIC REGRESSION | P=0.101N P=0.574 P=0.132N | P=0.424 P=0.295 P=0.512 |
|COCHRAN-ARMITAGE | P=0.179N | P=0.400 |
|FISHER EXACT | P=0.558 P=0.207N | P=0.301 P=0.500 |
|=================================================================================================================================|
| |
|Spleen |
| Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 0/26 (0%) 2/50 (4%) | 0/50 (0%) 0/23 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 6.9% | 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/33 (0%) 0/5 (0%) 2/29 (7%) | 0/36 (0%) 0/9 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- 731 (T) | --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.115 (e) P=0.210 | (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.115 (e) P=0.210 | (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.115 (e) P=0.210 | (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.117 | (e) |
|FISHER EXACT | (e) P=0.253 | (e) (e) |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Carcinoma or Papilloma Squamous |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 3/48 (6%) 8/50 (16%) | 3/50 (6%) 3/49 (6%) 1/50 (2%) |
|ADJUSTED (b) | 5.1% 11.1% 20.5% | 8.0% 8.6% 2.9% |
|TERMINAL (d) | 1/33 (3%) 3/27 (11%) 2/29 (7%) | 2/36 (6%) 3/35 (9%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 542 731 (T) 469 | 697 731 (T) 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.024 * P=0.412 P=0.044 * | P=0.262N P=0.647 P=0.332N |
|INCIDENTAL TUMOR | P=0.028 * P=0.447 P=0.055 | P=0.203N P=0.635N P=0.230N |
|LOGISTIC REGRESSION | P=0.026 * P=0.438 P=0.054 | P=0.251N P=0.658 P=0.315N |
|COCHRAN-ARMITAGE | P=0.026 * | P=0.239N |
|FISHER EXACT | P=0.480 P=0.046 * | P=0.651 P=0.309N |
|=================================================================================================================================|
| |
|Stomach, Forestomach |
| Squamous Cell Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 3/48 (6%) 7/50 (14%) | 3/50 (6%) 3/49 (6%) 1/50 (2%) |
|ADJUSTED (b) | 5.1% 11.1% 18.7% | 8.0% 8.6% 2.9% |
|TERMINAL (d) | 1/33 (3%) 3/27 (11%) 2/29 (7%) | 2/36 (6%) 3/35 (9%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 542 731 (T) 550 | 697 731 (T) 731 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.044 * P=0.412 P=0.073 | P=0.262N P=0.647 P=0.332N |
|INCIDENTAL TUMOR | P=0.058 P=0.447 P=0.104 | P=0.203N P=0.635N P=0.230N |
|LOGISTIC REGRESSION | P=0.048 * P=0.438 P=0.086 | P=0.251N P=0.658 P=0.315N |
|COCHRAN-ARMITAGE | P=0.050 * | P=0.239N |
|FISHER EXACT | P=0.480 P=0.080 | P=0.651 P=0.309N |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 3/50 (6%) 1/49 (2%) 0/50 (0%) |
|ADJUSTED (b) | | 7.9% 2.9% 0.0% |
|TERMINAL (d) | | 2/36 (6%) 1/35 (3%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | | 633 731 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.063N P=0.310N P=0.124N |
|INCIDENTAL TUMOR | | P=0.090N P=0.326N P=0.203N |
|LOGISTIC REGRESSION | | P=0.062N P=0.310N P=0.123N |
|COCHRAN-ARMITAGE | | P=0.061N |
|FISHER EXACT | | P=0.316N P=0.121N |
|=================================================================================================================================|
| |
|All Organs |
| Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/48 (0%) 2/50 (4%) | 0/50 (0%) 1/49 (2%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 6.9% | 0.0% 2.9% 0.0% |
|TERMINAL (d) | 0/33 (0%) 0/27 (0%) 2/29 (7%) | 0/36 (0%) 1/35 (3%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- 731 (T) | --- 731 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.087 (e) P=0.210 | P=0.722 P=0.494 (e) |
|INCIDENTAL TUMOR | P=0.087 (e) P=0.210 | P=0.722 P=0.494 (e) |
|LOGISTIC REGRESSION | P=0.087 (e) P=0.210 | P=0.722 P=0.494 (e) |
|COCHRAN-ARMITAGE | P=0.097 | P=0.730 |
|FISHER EXACT | (e) P=0.247 | P=0.495 (e) |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 3/48 (6%) 3/50 (6%) | 3/50 (6%) 1/49 (2%) 0/50 (0%) |
|ADJUSTED (b) | 10.7% 9.8% 8.7% | 7.7% 2.9% 0.0% |
|TERMINAL (d) | 2/33 (6%) 2/27 (7%) 1/29 (3%) | 2/36 (6%) 1/35 (3%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 664 549 623 | 596 731 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.470N P=0.605N P=0.546N | P=0.066N P=0.310N P=0.131N |
|INCIDENTAL TUMOR | P=0.380N P=0.575N P=0.447N | P=0.090N P=0.326N P=0.203N |
|LOGISTIC REGRESSION | P=0.435N P=0.563N P=0.513N | P=0.062N P=0.312N P=0.119N |
|COCHRAN-ARMITAGE | P=0.421N | P=0.061N |
|FISHER EXACT | P=0.523N P=0.500N | P=0.316N P=0.121N |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 3/48 (6%) 5/50 (10%) | 3/50 (6%) 2/49 (4%) 0/50 (0%) |
|ADJUSTED (b) | 10.7% 9.8% 15.3% | 7.7% 5.7% 0.0% |
|TERMINAL (d) | 2/33 (6%) 2/27 (7%) 3/29 (10%) | 2/36 (6%) 2/35 (6%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 664 549 623 | 596 731 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.377 P=0.605N P=0.442 | P=0.090N P=0.506N P=0.131N |
|INCIDENTAL TUMOR | P=0.455 P=0.575N P=0.529 | P=0.118N P=0.522N P=0.203N |
|LOGISTIC REGRESSION | P=0.407 P=0.563N P=0.475 | P=0.084N P=0.507N P=0.119N |
|COCHRAN-ARMITAGE | P=0.427 | P=0.083N |
|FISHER EXACT | P=0.523N P=0.500 | P=0.510N P=0.121N |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 15
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma And Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 9/50 (18%) 2/48 (4%) 3/50 (6%) | 15/50 (30%) 12/49 (24%) 18/50 (36%) |
|ADJUSTED (b) | 24.2% 6.1% 10.3% | 33.9% 29.0% 42.1% |
|TERMINAL (d) | 6/33 (18%) 1/27 (4%) 3/29 (10%) | 8/36 (22%) 6/35 (17%) 10/34 (29%) |
|FIRST INCIDENCE (DAYS) | 600 537 731 (T) | 409 617 474 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.050N P=0.063N P=0.096N | P=0.277 P=0.358N P=0.318 |
|INCIDENTAL TUMOR | P=0.036N* P=0.036N* P=0.064N | P=0.273 P=0.312N P=0.198 |
|LOGISTIC REGRESSION | P=0.037N* P=0.042N* P=0.074N | P=0.246 P=0.355N P=0.353 |
|COCHRAN-ARMITAGE | P=0.030N* | P=0.293 |
|FISHER EXACT | P=0.030N* P=0.061N | P=0.349N P=0.335 |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 9/50 (18%) 2/48 (4%) 3/50 (6%) | 14/50 (28%) 12/49 (24%) 18/50 (36%) |
|ADJUSTED (b) | 24.2% 6.1% 10.3% | 32.5% 29.0% 42.1% |
|TERMINAL (d) | 6/33 (18%) 1/27 (4%) 3/29 (10%) | 8/36 (22%) 6/35 (17%) 10/34 (29%) |
|FIRST INCIDENCE (DAYS) | 600 537 731 (T) | 574 617 474 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.050N P=0.063N P=0.096N | P=0.213 P=0.433N P=0.252 |
|INCIDENTAL TUMOR | P=0.036N* P=0.036N* P=0.064N | P=0.197 P=0.352N P=0.137 |
|LOGISTIC REGRESSION | P=0.037N* P=0.042N* P=0.074N | P=0.187 P=0.435N P=0.221 |
|COCHRAN-ARMITAGE | P=0.030N* | P=0.221 |
|FISHER EXACT | P=0.030N* P=0.061N | P=0.433N P=0.260 |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 16
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 18/50 (36%) 13/48 (27%) 26/50 (52%) | 20/50 (40%) 13/49 (27%) 17/50 (34%) |
|ADJUSTED (b) | 48.9% 40.5% 69.6% | 51.1% 33.7% 47.1% |
|TERMINAL (d) | 15/33 (45%) 9/27 (33%) 18/29 (62%) | 17/36 (47%) 10/35 (29%) 15/34 (44%) |
|FIRST INCIDENCE (DAYS) | 530 446 550 | 629 623 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.030 * P=0.413N P=0.035 * | P=0.359N P=0.119N P=0.411N |
|INCIDENTAL TUMOR | P=0.040 * P=0.324N P=0.049 * | P=0.297N P=0.092N P=0.380N |
|LOGISTIC REGRESSION | P=0.041 * P=0.336N P=0.051 | P=0.320N P=0.047N* P=0.366N |
|COCHRAN-ARMITAGE | P=0.062 | P=0.298N |
|FISHER EXACT | P=0.232N P=0.079 | P=0.113N P=0.339N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 29/50 (58%) 26/48 (54%) 18/50 (36%) | 18/50 (36%) 18/49 (37%) 22/50 (44%) |
|ADJUSTED (b) | 59.2% 64.5% 43.0% | 39.0% 40.5% 49.1% |
|TERMINAL (d) | 13/33 (39%) 13/27 (48%) 7/29 (24%) | 9/36 (25%) 9/35 (26%) 12/34 (35%) |
|FIRST INCIDENCE (DAYS) | 509 448 423 | 409 454 282 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.106N P=0.412 P=0.109N | P=0.234 P=0.556 P=0.264 |
|INCIDENTAL TUMOR | P=0.007N** P=0.529N P=0.008N** | P=0.181 P=0.485 P=0.163 |
|LOGISTIC REGRESSION | P=0.009N** P=0.471N P=0.008N** | P=0.188 P=0.501 P=0.234 |
|COCHRAN-ARMITAGE | P=0.018N* | P=0.236 |
|FISHER EXACT | P=0.429N P=0.022N* | P=0.553 P=0.270 |
|=================================================================================================================================|
DATE: 09/05/94 EXPERIMENT: 05038 TEST: 02 PAGE 17
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- DIMETHOXANE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | 0 MG/KG 250 MG/ 500 MG/ | 0 MG/KG 250 MG/ 500 MG/ |
| | KG KG | KG KG |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 38/50 (76%) 31/48 (65%) 37/50 (74%) | 32/50 (64%) 26/49 (53%) 33/50 (66%) |
|ADJUSTED (b) | 77.6% 75.2% 83.8% | 67.8% 57.6% 73.0% |
|TERMINAL (d) | 22/33 (67%) 17/27 (63%) 22/29 (76%) | 21/36 (58%) 16/35 (46%) 22/34 (65%) |
|FIRST INCIDENCE (DAYS) | 509 446 423 | 409 454 282 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.372 P=0.550N P=0.394 | P=0.389 P=0.234N P=0.415 |
|INCIDENTAL TUMOR | P=0.483N P=0.266N P=0.512N | P=0.420 P=0.201N P=0.362 |
|LOGISTIC REGRESSION | P=0.474N P=0.207N P=0.541N | P=0.471 P=0.189N P=0.511 |
|COCHRAN-ARMITAGE | P=0.456N | P=0.459 |
|FISHER EXACT | P=0.155N P=0.500N | P=0.184N P=0.500 |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).
--multipart-boundary
Content-type: text/plain
Range: bytes 119000-119000/119000
--multipart-boundary--